Please note that maintenance work is scheduled between 4 AM and 5 AM - CET.
During this time, you may experience reduced performance.
Thanks for your patience.
in (world ranking)
Sebastiano Buti, PhD
Oncology — University Hospitals Parma Medical Center, United States
Sebastiano Buti
Joined Nov 2025
University Hospitals Parma Medical Center · Oncology
Top 1% Worldwide expert in Kidney Neoplasms, Urologic Neoplasms, Carcinoma, Urogenital Neoplasms
CARE1 FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA 2023-503317-29-00 — cells, carcinoma, renal cell, therapeutics, carcinoma
Phase 3
Recruiting
2024
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK 6482 033) 2024-517136-21-00 — cells, neoplasms, kidney, carcinoma, renal cell, respect, kidney neoplasms, therapeutics, carcinoma
Phase 3
Recruiting
2025
Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma 2023-505177-32-00 — cells, nephrectomy, metastasectomy, rna, messenger, carcinoma, renal cell, therapeutics, carcinoma
Phase 2
Active not recruiting
2024
Phase 2 3 Trial of Izalontamab Brengitecan vs Platinum based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy 2025-522400-24-00 — neoplasms, disease progression, drug therapy, immunotherapy, therapeutics, chemotherapy
Phase 2/Phase 3
Recruiting
2026
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY THE ITALIC RCC RANDOMIZED STUDY 2024-517789-41-00 — cells, neoplasms, carcinoma, renal cell, carcinoma
To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.
Functional
Always active
Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Storage or technical access used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.